Scientific Posters , Honolulu Acoziborole Clinical and Mass Balance , Human ADME

A Single Dose Study to Assess the Mass Balance Recovery, Absorption, Metabolism, and Excretion of [14C]-Acoziborole in Healthy Male Subjects After Oral Dosing

8 October 2024
Overview

Acoziborole (Figure 1), an oxaborole-6 carboxamide, is being developed as an oral single dose treatment for Human African trypanosomiasis (also called "sleeping sickness"). As part of the overall development programme, the mass balance, pharmacokinetics, metabolism and excretion of acoziborole were studied in an open-label, phase 1 study. This poster will describe the mass balance and clinical safety assessments from the human ADME study. 

Download
Date
8 October 2024
Ask The Experts

Human ADME study questions? Get answers from our team.

Have a question about your next human ADME program or other clinical pharmacology programs that we offer? Ask a member of our team about our capabilities.

 

Dr. Andrew Lewis

Chief Scientific Officer

Dr. Andrew (Andy) Lewis is the Chief Scientific Officer at Quotient Sciences. As the leader of Quotient Sciences' scientific teams...

About Andrew
Iain Shaw

Senior Director, 14C Enabled Drug Development

Iain Shaw has over 30 years of experience in the pharmaceutical industry, including over 15 years focused on 14C-enabled drug deve...

About Iain
Dr. Adam Robinson-Miller

Senior Manager, 14C Enabled Drug Development

Dr. Adam Robinson-Miller has more than a decade of experience in the pharmaceutical and OTC environments, with particular focus on...

About Adam
Get in touch
Humanity can't afford to wait, so neither can we.